This menu provides the list of EV miRNAs identified by high-throughput analyses.
Refresh all contents
Search:
Dataset accession
miRBase accession
Mature name
Orthologous group
Superdomain:
All
Prokaryote
Eukaryote
Filter datasets:
- "Sample type" indicates the source from which EVs originated (e.g. B cell, serum).
- "Sample status" indicates the condition of the source from which EVs originated (e.g. Normal, miR-146a-treated, Patients of hernia).
By species
Bos taurus
Homo sapiens
In vitro/In vivo
Ex vivo
In vitro
In vivo
By sample type
Adult fibroblast
B cell (Raji)
Blood
Bone marrow stromal cells
Bone marrow-derived mesenchymal stem cell (R14)
Breast cancer cell (MCF7)
Breast cancer cells (MDA-MB-231)
Colon cancer cell (HCT116)
Colon cancer cell (HT29)
Colon cancer cell (RKO)
Colon cancer cell (SW48)
Colon cancer cell (SW480)
Colorectal cancer cell (SW480)
Colorectal cancer cell (SW620)
Embryonic kidney cell (HEK293T)
Fetal human colon epithelial cell (FHC)
Gastric cancer cells (SGC-7901)
Liver cancer cells (CSQT-2)
Liver cancer cells (HCC-LM3)
Liver cancer cells (HepG2)
Liver cancer cells (MHCC-97L)
Lung cancer cell (DMS563)
Lung cancer cell (NCI_H69)
Lung cancer cell (SBC-3)
Lung cancer cells (A549)
Mast cell (HMC-1)
Metastatic gastric cacncer cell (AZP7a)
Metastatic gastric cancer cell (AZ521)
Oral cancer cells (HOC313-LM)
Pancreatic cancer cells (AsPC1, BxPC3, Capan1, Capan2, MiaPaca2, Panc1, Pt45P1, A818, Colo357, HD3577)
Plasma
Primary dendritic cell
Serum
T cell (Jurkat)
By sample status
Cisplatin-resistant
Colorectal cancer_stage1
Colorectal cancer_stage1_after_resection
Colorectal cancer_stage2
Colorectal cancer_stage2_after_resection
Colorectal cancer_stage3a
Colorectal cancer_stage3a_after_resection
Colorectal cancer_stage3b
Colorectal cancer_stage3b_after_resection
Colorectal cancer_stage4
Colorectal cancer_stage4_after_resection
Extremely severe hand, foot, and mouth disease
Fetal bovine serum
Healthy_timepoint1
Healthy_timepoint2
High density
Mild hand, foot, and mouth disease
Multiple myeloma patients
Multiple sclerosis
Normal
Normal_Agilent
Normal_Exiqon
Pancreatic cancer patient_Agilent
Pancreatic cancer patient_Exiqon
Pollen allergy_timepoint1
Pollen allergy_timepoint2
Sample A_Biooscientific
Sample A_Illumina
Sample A_NEB
Sample B_Biooscientific
Sample B_NEB
Sample C_NEB
Type 1 diabetes
miR-146a-treated
shDicer-transfected
Maximum false positive rate (FPR):
Maximum true positive rate (TPR):
- FPR is the probability that an absent miRNA accidently have higher intensity than that miRNA.
- TPR is the percentile of miRNA among the present miRNAs.
Please see user manual in the contact us/help menu for detail.
Number of molecules in one page:
100
200
All
The downloaded CSV file is not exactly the same as the displayed table. Opening CSV file with Excel can impair its content.
Since there are multiple primers in the microarray, the same miRNA can have several FPR and TPR values.
Mature name
miRBase accession
FPR
TPR
Publication
Orthologous group
Identification count
All / Prokaryote / Eukaryote
(FPR<0.05,TPR<0.5)
hsa-miR-451a
MIMAT0001631
0.0e+0
2.5e-2
MicroRNA expression profile in exosome discriminates extremely severe infections from mild infections for hand, foot and mouth disease.
BMC Infect Dis. 2014 Sep 17;14(1):506. doi: 10.1186/1471-2334-14-506.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
1.1e-2
MicroRNA expression profile in exosome discriminates extremely severe infections from mild infections for hand, foot and mouth disease.
BMC Infect Dis. 2014 Sep 17;14(1):506. doi: 10.1186/1471-2334-14-506.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
2.2e-2
MicroRNA expression profile in exosome discriminates extremely severe infections from mild infections for hand, foot and mouth disease.
BMC Infect Dis. 2014 Sep 17;14(1):506. doi: 10.1186/1471-2334-14-506.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
9.5e-3
MicroRNA expression profile in exosome discriminates extremely severe infections from mild infections for hand, foot and mouth disease.
BMC Infect Dis. 2014 Sep 17;14(1):506. doi: 10.1186/1471-2334-14-506.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
1.6e-2
MicroRNA expression profile in exosome discriminates extremely severe infections from mild infections for hand, foot and mouth disease.
BMC Infect Dis. 2014 Sep 17;14(1):506. doi: 10.1186/1471-2334-14-506.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
9.7e-3
MicroRNA expression profile in exosome discriminates extremely severe infections from mild infections for hand, foot and mouth disease.
BMC Infect Dis. 2014 Sep 17;14(1):506. doi: 10.1186/1471-2334-14-506.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
2.1e-2
MicroRNA expression profile in exosome discriminates extremely severe infections from mild infections for hand, foot and mouth disease.
BMC Infect Dis. 2014 Sep 17;14(1):506. doi: 10.1186/1471-2334-14-506.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
9.7e-3
MicroRNA expression profile in exosome discriminates extremely severe infections from mild infections for hand, foot and mouth disease.
BMC Infect Dis. 2014 Sep 17;14(1):506. doi: 10.1186/1471-2334-14-506.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
1.8e-2
MicroRNA expression profile in exosome discriminates extremely severe infections from mild infections for hand, foot and mouth disease.
BMC Infect Dis. 2014 Sep 17;14(1):506. doi: 10.1186/1471-2334-14-506.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
2.2e-2
MicroRNA expression profile in exosome discriminates extremely severe infections from mild infections for hand, foot and mouth disease.
BMC Infect Dis. 2014 Sep 17;14(1):506. doi: 10.1186/1471-2334-14-506.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
7.7e-2
Combined Evaluation of a Panel of Protein and miRNA Serum Exosome Biomarkers for Pancreatic Cancer Diagnosis Increases Sensitivity and Specificity.
Int J Cancer. 2014 Nov 12. doi: 10.1002/ijc.29324.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
1.2e-1
Combined Evaluation of a Panel of Protein and miRNA Serum Exosome Biomarkers for Pancreatic Cancer Diagnosis Increases Sensitivity and Specificity.
Int J Cancer. 2014 Nov 12. doi: 10.1002/ijc.29324.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
9.8e-2
Combined Evaluation of a Panel of Protein and miRNA Serum Exosome Biomarkers for Pancreatic Cancer Diagnosis Increases Sensitivity and Specificity.
Int J Cancer. 2014 Nov 12. doi: 10.1002/ijc.29324.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
8.5e-2
Combined Evaluation of a Panel of Protein and miRNA Serum Exosome Biomarkers for Pancreatic Cancer Diagnosis Increases Sensitivity and Specificity.
Int J Cancer. 2014 Nov 12. doi: 10.1002/ijc.29324.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
9.9e-2
Combined Evaluation of a Panel of Protein and miRNA Serum Exosome Biomarkers for Pancreatic Cancer Diagnosis Increases Sensitivity and Specificity.
Int J Cancer. 2014 Nov 12. doi: 10.1002/ijc.29324.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
3.4e-1
Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis.
Cancer Cell. 2014 Nov 10;26(5):707-721. doi: 10.1016/j.ccell.2014.09.005. Epub 2014 Oct 23.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
1.2e-1
Two distinct extracellular RNA signatures released by a single cell type identified by microarray and next-generation sequencing.
RNA Biol. 2016 Oct 28:0.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
3.4e-1
Exosomal microRNA miR-1246 induces cell motility and invasion through the regulation of DENND2D in oral squamous cell carcinoma.
Sci Rep. 2016 Dec 8;6:38750. doi: 10.1038/srep38750.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
1.2e-1
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
9.2e-2
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
3.4e-1
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
3.0e-1
Cisplatin-resistant lung cancer cell-derived exosomes increase cisplatin resistance of recipient cells in exosomal miR-100-5p-dependent manner.
Int J Nanomedicine. 2017 May 15;12:3721-3733. doi: 10.2147/IJN.S131516. eCollection 2017.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
1.3e-2
Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes.
Sci Rep. 2017 Jul 20;7(1):5998. doi: 10.1038/s41598-017-05787-y.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
5.1e-3
Plasma-derived exosome characterization reveals a distinct microRNA signature in long duration Type 1 diabetes.
Sci Rep. 2017 Jul 20;7(1):5998. doi: 10.1038/s41598-017-05787-y.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
2.5e-1
Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes.
Am J Cancer Res. 2017 Sep 1;7(9):1913-1925. eCollection 2017.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
1.5e-1
Tumor microenvironment interruption: a novel anti-cancer mechanism of Proton-pump inhibitor in gastric cancer by suppressing the release of microRNA-carrying exosomes.
Am J Cancer Res. 2017 Sep 1;7(9):1913-1925. eCollection 2017.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
3.1e-5
3.1e-5
Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis.
Nat Commun. 2018 Jan 2;9(1):17. doi: 10.1038/s41467-017-02406-2.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
3.7e-5
3.7e-5
Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis.
Nat Commun. 2018 Jan 2;9(1):17. doi: 10.1038/s41467-017-02406-2.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
1.8e-2
1.8e-2
Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis.
Blood Adv. 2017 May 16;1(13):812-823. doi: 10.1182/bloodadvances.2016003251. eCollection 2017 May 23.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
5.0e-4
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
0.0e+0
7.3e-2
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
9.0e-4
9.0e-4
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000148_1
104
/
0
/
104
hsa-miR-451a
MIMAT0001631
3.1e-3
3.1e-3
Tumor-derived exosomal miR-1247-3p induces cancer-associated fibroblast activation to foster lung metastasis of liver cancer.
Nat Commun. 2018 Jan 15;9(1):191. doi: 10.1038/s41467-017-02583-0.
MIPF0000148_1
104
/
0
/
104
<
[5]